Results for tag: "Antibody Fragment"

The Antibody Fragment market within the context of Oncology Drugs is a rapidly growing field of biotechnology. Antibody Fragments are small pieces of antibodies that are used to target and treat cancer cells. They are designed to bind to specific antigens on the surface of cancer cells, allowing them to be targeted and destroyed. Antibody Fragments are also used to deliver drugs directly to cancer cells, increasing the effectiveness of the drug. This technology has been used to develop a variety of cancer treatments, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The Antibody Fragment market is expected to continue to grow as new treatments are developed and approved. This growth is driven by the increasing prevalence of cancer, as well as the need for more effective treatments. Some companies in the Antibody Fragment market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more